/SEPN
SEPN Stock - Septerna, Inc.
Healthcare|BiotechnologyNASDAQ
$29.58+7.41%
+$2.04 (+7.41%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).75
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+12.7%upside
Target: $33.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SEPN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$29.28 – $29.88
TARGET (TP)$33.33
STOP LOSS$27.21
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.80
52W High$30.50
52W Low$4.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $1.07M | $151,000 | N/A |
| Gross Profit | $1.07M | $151,000 | N/A |
| Gross Margin | 100.0% | 100.0% | N/A |
| Operating Income | $-80,823,000 | $2.08M | $-27,967,000 |
| Net Income | $-71,798,000 | $4.18M | $-27,676,000 |
| Net Margin | -6678.9% | 2768.2% | N/A |
| EPS | $-7.26 | $0.03 | $-1.42 |
Company Overview
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
1
20%
Buy / Outperform
3
60%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$35
Average Target
↑ 17.4% Upside
Now
$14
Low
$35
Average
$50
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | Raymond James | Initiation | Strong Buy | $38 |
| December 15th 2025 | Truist | Initiation | Buy | $34 |
| November 14th 2025 | Wells Fargo | Upgrade | Overweight | - |
| June 23rd 2025 | H.C. Wainwright | Initiation | Buy | $26 |
| February 18th 2025 | Wells Fargo | Downgrade | Equal Weight | $14 |
| November 19th 2024 | JP Morgan | Initiation | Overweight | $38 |
| November 19th 2024 | TD Cowen | Initiation | Buy | - |
| November 19th 2024 | Wells Fargo | Initiation | Overweight | $43 |
| November 19th 2024 | Cantor Fitzgerald | Initiation | Overweight | $50 |
Earnings History & Surprises
SEPNBeat Rate
20%
Last 5 quarters
Avg Surprise
-420.2%
EPS vs Estimate
Beats / Misses
1/4
Last 12 quarters
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q4 24
-912.0%
$-8.40vs$-0.83
Q1 25
+7.2%
$-0.64vs$-0.69
Q2 25
-28.9%
$-0.49vs$-0.38
Q3 25
-1020.0%
$-0.56vs$-0.05
Q4 25
-147.4%
$-0.09vs$0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.19 | $-0.09 | -147.4% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.05 | $-0.56 | -1020.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.38 | $-0.49 | -28.9% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.69 | $-0.64 | +7.2% | ✓ BEAT |
Q4 2024 | Nov 21, 2024 | $-0.83 | $-8.40 | -912.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | — | — | — | — |
Q4 2023 | Dec 31, 2023 | — | $2.05 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.56 | — | — |
Latest News
Septerna shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $38 price target.
📈 PositiveBenzinga•Dec 19, 2025, 05:42 PM
Raymond James Initiates Coverage On Septerna with Strong Buy Rating, Announces Price Target of $38
📈 PositiveBenzinga•Dec 19, 2025, 12:23 PM
Truist Securities Initiates Coverage On Septerna with Buy Rating, Announces Price Target of $34
📈 PositiveBenzinga•Dec 15, 2025, 01:52 PM
Wells Fargo Upgrades Septerna to Overweight, Raises Price Target to $28
📈 PositiveBenzinga•Nov 14, 2025, 01:48 PM
HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $30
📈 PositiveBenzinga•Nov 11, 2025, 12:43 PM
Septerna Q3 EPS $0.18, Inline, Sales $21.495M Miss $35.000M Estimate
📉 NegativeBenzinga•Nov 10, 2025, 12:45 PM
MBX surges 160% on mid-stage data for hypoparathyroidism drug canvuparatide
📈 PositiveSeeking Alpha•Sep 22, 2025, 02:20 PM•Also: , ,
Cantor Fitzgerald Reiterates Overweight on Septerna, Maintains $25 Price Target
📈 PositiveBenzinga•Sep 5, 2025, 01:52 PM
HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $26 Price Target
📈 PositiveBenzinga•Aug 21, 2025, 02:38 PM
Septerna Announces Dosing Of First Participants In Phase 1 Clinical Trial Of SEP-631, Selective Oral Small Molecule MRGPRX2 NAM Being Developed For Treatment Of CSU And Other Mast Cell-Driven Diseases
📈 PositiveBenzinga•Aug 21, 2025, 12:08 PM
Septerna Doses first Participants In Phase 1 Clinical Trial of SEP-631
📈 PositiveBenzinga•Aug 21, 2025, 12:06 PM
Novo Nordisk in pact with Septerna for oral obesity drugs
📈 PositiveSeeking Alpha•May 14, 2025, 11:24 AM•Also:
Frequently Asked Questions about SEPN
What is SEPN's current stock price?
Septerna, Inc. (SEPN) is currently trading at $29.58 per share. The stock has moved +7.41% today.
What is the analyst price target for SEPN?
The average analyst price target for SEPN is $33.33, based on 1 analyst.
What sector is Septerna, Inc. in?
Septerna, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SEPN's market cap?
Septerna, Inc. has a market capitalization of $1.32 billion, making it a small-cap company.
Does SEPN pay dividends?
No, Septerna, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
BCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
Explore stocks similar to SEPN for comparison